{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:32:14Z","timestamp":1786365134997,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research Collaboration","award":["NIHR127963"],"award-info":[{"award-number":["NIHR127963"]}]},{"DOI":"10.13039\/100013786","name":"Cure EB","doi-asserted-by":"publisher","award":["Cure EB"],"award-info":[{"award-number":["Cure EB"]}],"id":[{"id":"10.13039\/100013786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic skin condition causing fragile skin, blistering, and scarring. It leads to chronic pain, slow wound healing, and severe limitations, profoundly impacting patient and family quality of life. Umbilical cord tissue-derived mesenchymal stromal cells (UC-MSC) have shown therapeutic promise. The Mission EB trial (ISRCTN14409785; registration date 25\/03\/2021) assessed UC-MSC safety and effectiveness in children with RDEB in a placebo-controlled, double-blinded, crossover study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study used a qualitative research design with semi-structured interviews and thematic analysis, to explore Mission EB trial treatment impact on the quality of life of patients and parents. Parents and patients were interviewed at two time points (approximately 3- and 12-months post-randomisation). Purposive sampling included 10 parents and 6 children; 13 individuals (8 adults, 5 children) were interviewed twice (once in each study period). Interviews were transcribed verbatim, independently coded, with overall impressions agreed upon prior to unblinding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RDEB significantly impacted daily life, marked by pain and itch. Participants were hopeful of the trial, willing to pursue minor improvements. UC-MSC infusions led to reduced pain\/itchiness, improved wound healing, and resulted in fewer self-reported dressing changes. These benefits often translated to increased energy, improved eating, and greater daily activity participation. Benefits were more pronounced with active treatment. Negative effects were minimal, primarily venous access difficulties. Blinded participants could discern active UC-MSC from placebo based on symptom changes; 10 of 13 showed clear differences aligning with treatment. All parents interviewed expressed willingness for their child to receive treatment again.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This qualitative research provides valuable insights into perceived benefits of UC-MSC treatment for children with RDEB. Interview findings regarding symptom improvement and participants\u2019 ability to discern active treatment shed light on its perceived benefit in RDEB, especially in milder RDEB patients. The study highlights the critical importance of qualitative methodologies in adding to quantitative trial outcomes and capturing the meaningful impact of interventions on the lives of patients and families particularly where quantitative measures may not fully reflect lived experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04350-1","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:47:16Z","timestamp":1780505236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4468-7417","authenticated-orcid":false,"given":"Katie","family":"Biggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7094-3053","authenticated-orcid":false,"given":"Shamila","family":"Ditta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-7923","authenticated-orcid":false,"given":"Maria L.","family":"Bageta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9944-719X","authenticated-orcid":false,"given":"Pablo","family":"Lopez-Balboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-2844","authenticated-orcid":false,"given":"Kate","family":"Hutchence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6259-0822","authenticated-orcid":false,"given":"Diana","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-7636","authenticated-orcid":false,"given":"Steven","family":"Julious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-5447","authenticated-orcid":false,"given":"Cindy","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-0373","authenticated-orcid":false,"given":"Gabriela","family":"Petrof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-8008","authenticated-orcid":false,"given":"Anna E.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"3","key":"4350_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/erp.10.28","volume":"10","author":"C Pagliarello","year":"2010","unstructured":"Pagliarello C, Tabolli S. Factors affecting quality of life in epidermolysis bullosa. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):329\u201338.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"4350_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primer. 2020;6(1):78.","journal-title":"Nat Rev Dis Primer"},{"issue":"3","key":"4350_CR3","doi-asserted-by":"publisher","first-page":"110805","DOI":"10.1016\/j.humimm.2024.110805","volume":"85","author":"C Santucci","year":"2024","unstructured":"Santucci C, Alexandru M, Chen X, Mellerio JE, Karagiannis SN, Jack\u00f3w-Malinowska J. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Hum Immunol. 2024;85(3):110805.","journal-title":"Hum Immunol"},{"issue":"7","key":"4350_CR4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s11136-020-02495-5","volume":"29","author":"CCG Togo","year":"2020","unstructured":"Togo CCG, Zidorio APC, Gon\u00e7alves VSS, Hubbard L, De Carvalho KMB, Dutra ES. Quality of life in people with epidermolysis bullosa: a systematic review. Qual Life Res. 2020;29(7):1731\u201345.","journal-title":"Qual Life Res"},{"issue":"1","key":"4350_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","volume":"16","author":"JY Tang","year":"2021","unstructured":"Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4350_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2133.2002.04607.x","volume":"146","author":"HM Horn","year":"2002","unstructured":"Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. Br J Dermatol. 2002;146(2):267\u201374.","journal-title":"Br J Dermatol"},{"issue":"5","key":"4350_CR7","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jaad.2020.03.028","volume":"85","author":"VA Eng","year":"2021","unstructured":"Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, et al. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. J Am Acad Dermatol. 2021;85(5):1161\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"9\u201310","key":"4350_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/jocn.15209","volume":"29","author":"Y Wu","year":"2020","unstructured":"Wu Y, Sun F, Lee P. Family caregivers\u2019 lived experiences of caring for epidermolysis bullosa patients: A phenomenological study. J Clin Nurs. 2020;29(9\u201310):1552\u201360.","journal-title":"J Clin Nurs"},{"issue":"1","key":"4350_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","volume":"17","author":"JA Feinstein","year":"2022","unstructured":"Feinstein JA, Bruckner AL, Chastek B, Anderson A, Roman J. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):367.","journal-title":"Orphanet J Rare Dis"},{"key":"4350_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/TCRM.S386923","volume":"19","author":"PC Hou","year":"2023","unstructured":"Hou PC, Del Agua N, Lwin SM, Hsu CK, McGrath JA. Innovations in the Treatment of Dystrophic Epidermolysis Bullosa (DEB): Current Landscape and Prospects. Ther Clin Risk Manag. 2023;19:455\u201373.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"4350_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s12015-024-10697-4","volume":"20","author":"R Raoufinia","year":"2024","unstructured":"Raoufinia R, Rahimi HR, Keyhanvar N, Moghbeli M, Abdyazdani N, Rostami M, et al. Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy. Stem Cell Rev Rep. 2024;20(5):1200\u201312.","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"4350_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.20910","volume":"186","author":"KS Subramaniam","year":"2022","unstructured":"Subramaniam KS, Antoniou MN, McGrath JA, Lwin SM. The potential of gene therapy for recessive dystrophic epidermolysis bullosa*. Br J Dermatol. 2022;186(4):609\u201319.","journal-title":"Br J Dermatol"},{"issue":"9","key":"4350_CR13","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1038\/jid.2015.158","volume":"135","author":"G Petrof","year":"2015","unstructured":"Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, et al. Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa. J Invest Dermatol. 2015;135(9):2319\u201321.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"4350_CR14","doi-asserted-by":"publisher","first-page":"e143606","DOI":"10.1172\/jci.insight.143606","volume":"6","author":"SE Lee","year":"2021","unstructured":"Lee SE, Lee SJ, Kim SE, Kim K, Cho B, Roh K, et al. Intravenous allogeneic umbilical cord blood\u2013derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients. JCI Insight. 2021;6(2):e143606.","journal-title":"JCI Insight"},{"issue":"5","key":"4350_CR15","doi-asserted-by":"publisher","first-page":"e089857","DOI":"10.1136\/bmjopen-2024-089857","volume":"15","author":"ML Bageta","year":"2025","unstructured":"Bageta ML, L\u00f3pez-Balboa P, Dimairo M, Glover R, Hutchence K, Papaioannou D, et al. Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extension. BMJ Open. 2025;15(5):e089857.","journal-title":"BMJ Open"},{"key":"4350_CR16","doi-asserted-by":"publisher","first-page":"103417","DOI":"10.1016\/j.eclinm.2025.103417","volume":"88","author":"ML Bageta","year":"2025","unstructured":"Bageta ML, Lopez-Balboa P, Bursnall M, Glover R, Hutchence K, Papaioannou D, et al. Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase. eClinicalMedicine. 2025;88:103417.","journal-title":"eClinicalMedicine"},{"issue":"1","key":"4350_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/bjd\/ljad077","volume":"189","author":"EWH Korte","year":"2023","unstructured":"Korte EWH, Welponer T, Kottner J, Van Der Werf S, Van Den Akker PC, Horv\u00e1th B, et al. Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: a scoping review as a first step towards outcome harmonization. Br J Dermatol. 2023;189(1):80\u201390.","journal-title":"Br J Dermatol"},{"issue":"3","key":"4350_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/bjd\/ljae200","volume":"191","author":"EWH Korte","year":"2024","unstructured":"Korte EWH, Pasmooij AMG, Bolling MC, Hickey S, Hussain S, Kiritsi D, et al. Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa. Br J Dermatol. 2024;191(3):463\u20135.","journal-title":"Br J Dermatol"},{"issue":"1","key":"4350_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13(1):61.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4350_CR20","doi-asserted-by":"publisher","first-page":"e14128","DOI":"10.1111\/hex.14128","volume":"27","author":"JM Mart\u00ednez-Ripoll","year":"2024","unstructured":"Mart\u00ednez-Ripoll JM, Garc\u00eda\u2010Domingo M, De La Fuente Robles YM. Epidermolysis Bullosa in Spain: A Qualitative Analysis of Its Social Impact on Families With Diagnosed Minors. Health Expect. 2024;27(4):e14128.","journal-title":"Health Expect"},{"key":"4350_CR21","doi-asserted-by":"crossref","unstructured":"Chateau AV, Blackbeard D, Aldous C, Dlova N, Shaw CM. The impact, perceptions and needs of parents of children with epidermolysis bullosa. S Afr Fam Pract [Internet]. 2024 Jun 6 [cited 2026];66(1). Available from: https:\/\/safpj.co.za\/index.php\/safpj\/article\/view\/5897.","DOI":"10.4102\/SAFP.v66i1.5897"},{"issue":"4","key":"4350_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/pde.14656","volume":"38","author":"N Sangha","year":"2021","unstructured":"Sangha N, MacLellan AN, Pope E. Psychosocial impact of epidermolysis bullosa on patients: A qualitative study. Pediatr Dermatol. 2021;38(4):819\u201324.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"4350_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"4350_CR24","unstructured":"Lumivero [Internet]. [cited 2026 Jan 13]. NVivo: Leading Qualitative Data Analysis Software. Available from: https:\/\/lumivero.com\/products\/nvivo\/."},{"issue":"3","key":"4350_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2214.2006.00608.x","volume":"32","author":"S Kr\u00e4henb\u00fchl","year":"2006","unstructured":"Kr\u00e4henb\u00fchl S, Blades M. The effect of interviewing techniques on young children\u2019s responses to questions. Child Care Health Dev. 2006;32(3):321\u201331.","journal-title":"Child Care Health Dev"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04350-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:03:50Z","timestamp":1786363430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04350-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4350"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04350-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the North East York Research Ethics Committee (reference 21\/NE\/0016). Ethical approval for the interviews were sought alongside the trial ethical approval with an amendment on 4th March 2022. Participants were given an information sheet relating to the interviews once they had been recruited to the main trial and written consent was taken prior to the interviews.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AEM has received payment or honoraria for lectures, presentations or educational events from Amryt Pharma and Krystal Biotech and investigator in current clinical trial with TWi Biotechnology. GP has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events, from Amryt Pharma, Sanofi, Krystal Biotech, Pfizer, and Incyte. PLB and MLB are involved in previous and current clinical trials with Rheacell GmbH & Co. KG. MLB is a co-investigator in current clinical trials with TWi biotechnology. All other authors declare that they have no competing interests. INmune Bio provided the cells for the trial, but they had no input to the conduct or interpretation of the trial or the qualitative study and the clinicians listed above with competing interests were not involved in the conduct of the interviews and did not undertake analysis, but delivered the trial and helped with the interpretation.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"272"}}